Cabiralizumab  (Synonyms: FPA 008; Anti-Human CSF1R Recombinant Antibody)

Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research^[1][2][3][4].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

CSF1R/M-CSFR/CD115

Cabiralizumab (7 days) disrupts circulating tumor cells (CTC) cluster formation and increases CTC apoptosis in pancreatic ductal adenocarcinoma (PDAC) patient portal blood mononuclear cells (PortalBMC) unsorted samples^[4].
Cabiralizumab (7 days) can re-activate PDAC patient T cells (CD3+CD25+CTLA4-PD1L1-) and increases IFNγproduction in PortalBMC^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cabiralizumab (200-400 μg; i.p.; twice a week for 5 times) (anti-CSF1R) has anti-tumor activity and are inferior at higher doses to lower doses in mice model ³.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1436  [NCBI]

P07333

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.02 kDa

1613144-80-1

Liquid

Colorless to light yellow

[Cabiralizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized Human M-CSFR/CSF1R Protein can bind Cabiralizumab. The EC₅₀ for this effect is 2.465 ng/mL.
• 
  Flow cytometric analysis of 1.5X10⁶ THP-1 cells labeling Cabiralizumab (HY-P99259, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control.

• [1]. Weiss SA, et al. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clin Cancer Res. 2021 Sep 1;27(17):4757-4767.  [Content Brief]

  [2]. Peyraud F, et al. CSF-1R Inhibitor Development: Current Clinical Status. Curr Oncol Rep. 2017 Sep 5;19(11):70.  [Content Brief]

  [3]. Djureinovic D, et al. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Mol Cancer. 2023 Nov 14;22(1):182.  [Content Brief]

  [4]. Arnoletti JP, et al. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation. PLoS One. 2022 Mar 22;17(3):e0265725.  [Content Brief]